Cantor Fitzgerald Reiterates "Overweight" Rating for CG Oncology (NASDAQ:CGON)

CG Oncology (NASDAQ:CGON - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $75.00 target price on the stock. Cantor Fitzgerald's price objective would indicate a potential upside of 89.87% from the company's previous close.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set a "neutral" rating and a $42.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a research note on Thursday, April 4th. Finally, Morgan Stanley assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set an "overweight" rating and a $55.00 price objective for the company.

CG Oncology Stock Down 2.8 %

Shares of CGON traded down $1.12 during mid-day trading on Thursday, hitting $39.50. 639,036 shares of the company were exchanged, compared to its average volume of 615,708. CG Oncology has a 1-year low of $28.55 and a 1-year high of $50.23. The firm's 50 day simple moving average is $39.91.

Hedge Funds Weigh In On CG Oncology

A hedge fund recently bought a new stake in CG Oncology stock. Capstone Investment Advisors LLC bought a new position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 18,354 shares of the company's stock, valued at approximately $806,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.